Cargando…

Nox4 as a novel therapeutic target for diabetic vascular complications

Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongxia, Li, Jiaying, Luo, Gang, Zhou, Juan, Wang, Ning, Wang, Shanshan, Zhao, Rui, Cao, Xin, Ma, Yuxia, Liu, Gang, Hao, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363438/
https://www.ncbi.nlm.nih.gov/pubmed/37321060
http://dx.doi.org/10.1016/j.redox.2023.102781
_version_ 1785076625461739520
author Wang, Dongxia
Li, Jiaying
Luo, Gang
Zhou, Juan
Wang, Ning
Wang, Shanshan
Zhao, Rui
Cao, Xin
Ma, Yuxia
Liu, Gang
Hao, Liping
author_facet Wang, Dongxia
Li, Jiaying
Luo, Gang
Zhou, Juan
Wang, Ning
Wang, Shanshan
Zhao, Rui
Cao, Xin
Ma, Yuxia
Liu, Gang
Hao, Liping
author_sort Wang, Dongxia
collection PubMed
description Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases is a significant source of reactive oxygen species and plays a crucial role in regulating redox signaling, particularly in response to high glucose and diabetes mellitus. This review aims to provide an overview of the current knowledge about the role of Nox4 and its regulatory mechanisms in diabetic microangiopathies. Especially, the latest novel advances in the upregulation of Nox4 that aggravate various cell types within diabetic kidney disease will be highlighted. Interestingly, this review also presents the mechanisms by which Nox4 regulates diabetic microangiopathy from novel perspectives such as epigenetics. Besides, we emphasize Nox4 as a therapeutic target for treating microvascular complications of diabetes and summarize drugs, inhibitors, and dietary components targeting Nox4 as important therapeutic measures in preventing and treating diabetic microangiopathy. Additionally, this review also sums up the evidence related to Nox4 and diabetic macroangiopathy.
format Online
Article
Text
id pubmed-10363438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103634382023-07-25 Nox4 as a novel therapeutic target for diabetic vascular complications Wang, Dongxia Li, Jiaying Luo, Gang Zhou, Juan Wang, Ning Wang, Shanshan Zhao, Rui Cao, Xin Ma, Yuxia Liu, Gang Hao, Liping Redox Biol Review Article Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases is a significant source of reactive oxygen species and plays a crucial role in regulating redox signaling, particularly in response to high glucose and diabetes mellitus. This review aims to provide an overview of the current knowledge about the role of Nox4 and its regulatory mechanisms in diabetic microangiopathies. Especially, the latest novel advances in the upregulation of Nox4 that aggravate various cell types within diabetic kidney disease will be highlighted. Interestingly, this review also presents the mechanisms by which Nox4 regulates diabetic microangiopathy from novel perspectives such as epigenetics. Besides, we emphasize Nox4 as a therapeutic target for treating microvascular complications of diabetes and summarize drugs, inhibitors, and dietary components targeting Nox4 as important therapeutic measures in preventing and treating diabetic microangiopathy. Additionally, this review also sums up the evidence related to Nox4 and diabetic macroangiopathy. Elsevier 2023-06-09 /pmc/articles/PMC10363438/ /pubmed/37321060 http://dx.doi.org/10.1016/j.redox.2023.102781 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Wang, Dongxia
Li, Jiaying
Luo, Gang
Zhou, Juan
Wang, Ning
Wang, Shanshan
Zhao, Rui
Cao, Xin
Ma, Yuxia
Liu, Gang
Hao, Liping
Nox4 as a novel therapeutic target for diabetic vascular complications
title Nox4 as a novel therapeutic target for diabetic vascular complications
title_full Nox4 as a novel therapeutic target for diabetic vascular complications
title_fullStr Nox4 as a novel therapeutic target for diabetic vascular complications
title_full_unstemmed Nox4 as a novel therapeutic target for diabetic vascular complications
title_short Nox4 as a novel therapeutic target for diabetic vascular complications
title_sort nox4 as a novel therapeutic target for diabetic vascular complications
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363438/
https://www.ncbi.nlm.nih.gov/pubmed/37321060
http://dx.doi.org/10.1016/j.redox.2023.102781
work_keys_str_mv AT wangdongxia nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT lijiaying nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT luogang nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT zhoujuan nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT wangning nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT wangshanshan nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT zhaorui nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT caoxin nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT mayuxia nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT liugang nox4asanoveltherapeutictargetfordiabeticvascularcomplications
AT haoliping nox4asanoveltherapeutictargetfordiabeticvascularcomplications